Cefepime for prophylaxis of infections in the surgery of cholelithiasis. Results of a multicentric comparative trial.

A multicenter, open labelled, randomized study was carried out to compare the prophylactic efficacy of Cefepime and Ceftriaxone in patients undergoing biliary tract surgery. Two hundred and nine patients were included in the study and randomized to receive preoperative infusion of 2 g Cefepime (n=107) or 2 g Ceftriaxone (n=102) both in a single i.v. administration. Antimicrobial prophylaxis was successful in preventing infections in 98.9% of patients in the Cefepime group and 97.7% in the Ceftriaxone group (p=0.3871). Both regimens were well tolerated without any adverse drug-related reactions. A single dose of Cefepime seems to be a very useful alternative to other regimens for antibiotic prophylaxis of postoperative infectious complications in the elective surgical treatment of cholelithiasis.

[1]  Jerome J. Schentag,et al.  Once‐Daily Cefepime Versus Ceftriaxone for Nursing Home–Acquired Pneumonia , 2007, Journal of the American Geriatrics Society.

[2]  P. Gentileschi,et al.  Antibiotic prophylaxis in elective laparoscopic cholecystectomy: lack of need or lack of evidence? , 2004, Surgical Endoscopy And Other Interventional Techniques.

[3]  M. Schaller,et al.  Cefepime versus Imipenem-Cilastatin for Treatment of Nosocomial Pneumonia in Intensive Care Unit Patients: a Multicenter, Evaluator-Blind, Prospective, Randomized Study , 2003, Antimicrobial Agents and Chemotherapy.

[4]  L. Wise,et al.  Mini-Laparotorny Cholecystectomy in the Era of Laparoscopic Cholecystectomy: A Community-Based Hospital Perspective , 2003, The American surgeon.

[5]  W. Schwesinger,et al.  Laparoscopic cholecystectomy for elderly patients: gold standard for golden years? , 2003, Archives of surgery.

[6]  D. Figgitt,et al.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. , 2002, Drugs.

[7]  E. Targarona,et al.  Laparoscopic surgery and surgical infection , 2000, The British journal of surgery.

[8]  W. P. Ledet,et al.  Minicholecystectomy: a safe, cost-effective day surgery procedure. , 1999, Archives of surgery.

[9]  P. Biron,et al.  Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer). , 1998, The Journal of antimicrobial chemotherapy.

[10]  H. Lippert,et al.  Antimicrobial Prophylaxis in Laparoscopic and Conventional Cholecystectomy , 1998, Chemotherapy.

[11]  M. Zervos,et al.  Cefepime versus Ceftriaxone for Empiric Treatment of Hospitalized Patients with Community-Acquired Pneumonia , 1998, Antimicrobial Agents and Chemotherapy.

[12]  P. Biron.  Cefepime versus imipenem-cilastin as empirical monotherapy in 400 febrile patients with short duration neutropenia , 1998 .

[13]  H. Lippert,et al.  Antimicrobial prophylaxis in laparoscopic and conventional cholecystectomy . Conclusions of a large prospective multicenter quality assurance study in Germany. , 1998, Chemotherapy.

[14]  R. Davis,et al.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections. , 1994, PharmacoEconomics.

[15]  E. Croce,et al.  Laparocholecystectomy. 6,865 cases from Italian institutions. , 1994, Surgical endoscopy.

[16]  H. Bryson,et al.  A REVIEW OF THIS ANTIBACTERIAL ACTIVITY, PHARMACOKINETICS PROPERTIES AND THERAPEUTIC USE , 1994 .

[17]  P. Heseltine,et al.  A randomized study of cefepime versus the combination of gentamicin and meziocillin as an adjunct to surgical treatment in patients with acute cholecystitis , 1994, Surgery, gynecology & obstetrics.

[18]  A. Ehrhardt,et al.  β-Lactam resistance amongst Enterobacter species , 1993 .

[19]  C. Grassi,et al.  Cefepime: overview of activity in vitro and in vivo. , 1993, The Journal of antimicrobial chemotherapy.

[20]  A. Ehrhardt,et al.  beta-Lactam resistance amongst Enterobacter species. , 1993, The Journal of antimicrobial chemotherapy.

[21]  S. Wilson,et al.  Cefepime for infections of the biliary tract. , 1993, Surgery, gynecology & obstetrics.

[22]  C. Sanders.  beta-Lactamases of gram-negative bacteria: new challenges for new drugs. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  W J Martone,et al.  Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. , 1991, The American journal of medicine.

[24]  R. Hancock,et al.  Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae , 1991, Antimicrobial Agents and Chemotherapy.

[25]  P. Schmitz,et al.  Meta‐analysis of randomized, controlled clinical trials of antibiotic prophylaxis in biliary tract surgery , 1990, The British journal of surgery.

[26]  R. N. Brogden,et al.  Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration. , 1988, Drugs.

[27]  H. Neu,et al.  β-Lactam Antibiotics: Structural Relationships Affecting in Vitro Activity and Pharmacologic Properties , 1986 .

[28]  C. Sanders,et al.  Microbial resistance to newer generation beta-lactam antibiotics: clinical and laboratory implications. , 1985, The Journal of infectious diseases.

[29]  Price Ke,et al.  Basic design of beta-lactam antibiotics--cephalosporins. , 1984 .

[30]  K. E. Price,et al.  Basic design of beta-lactam antibiotics--cephalosporins. , 1984, Scandinavian Journal of Infectious Diseases. Supplementum.

[31]  M. Sianesi,et al.  [Peroperative antibiotic therapy in biliary surgical diseases]. , 1982, Acta bio-medica de L'Ateneo parmense : organo della Societa di medicina e scienze naturali di Parma.